Clinical trial
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
NCT06274801 is registered in ClinicalTrials.gov with Gossamer Bio USA, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Gossamer Bio USA, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 3, 2024
- Completion date
- December 31, 2026
- Enrollment
- 330 (estimated)
- Sites
- 120
Conditions
As the registry lists them; a condition with its own page is linked.